Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Little DIPPER: Safety and PK of AZD3152 in Healthy Adults
NCT05872958Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2023
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sipavibart in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by AstraZeneca. Primary endpoints: Adverse Events at Day 91, Serious Adverse Events at Day 365 and 12 more. Started May 2023; status: completed.
02
Drugs
sipavibart
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05872958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05872958.